Renal damage associated to intravitreal administration of ranibizumab

Morales, Enrique; Moliz, Candela; Gutiérrez, Eduardo

doi:10.1016/j.nefroe.2017.10.007

Cited by 12 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20,28,29,31,33,34 The literature has documented several case reports of the nephrotoxicity of agents that target VEGF and related signaling pathways. 20,[22][23][24]30,31,33,34,[36][37][38][39][40][41][42][43][44][45][46][47][48] Figure 1 summarizes the cellular pathways affected by VEGF and related signaling system blockade. 49…”

Section: Systemic Use Of Anti-vegf Agents: Renal and Extra Renal Effectsmentioning

confidence: 99%

“…Despite increasing numbers of case reports, it is not well recognized that the use of intravitreal anti-VEGF agents can result in endothelial toxicity and renal injury. 21,31,36,40,41,43,[46][47][48]59,60 A spectrum of side effects has been documented, which include worsening of baseline hypertension 21 or the development of de novo hypertension. 61,62 The development of proteinuria, malignant hypertension, TMA, and nephrotic syndrome have also been reported.…”

Section: Intravitreal Anti-vegf Administration: Systemic Absorptionmentioning

confidence: 99%

“…36 Morales et al reported a case of decreased eGFR in a patient with biopsy-proven diabetic nephropathy after the injection of ranibizumab intravitreally. 46 Pelle et al reported a patient with TMA after intravitreal injection of ranibizumab. 47 Perez-Valdivia et al 48 and Sato et al 43 each reported a case of relapse of minimal change disease after intravitreal injections of bevacizumab.…”

Section: Intravitreal Anti-vegf Administration: Systemic Absorptionmentioning

confidence: 99%

See 2 more Smart Citations

Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence

Hanna

Barsoum

Arman

et al. 2019

Kidney International

View full text Add to dashboard Cite

Section: Systemic Use Of Anti-vegf Agents: Renal and Extra Renal Effectsmentioning

confidence: 99%

Section: Intravitreal Anti-vegf Administration: Systemic Absorptionmentioning

confidence: 99%

Section: Intravitreal Anti-vegf Administration: Systemic Absorptionmentioning

confidence: 99%

See 1 more Smart Citation

Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence

Hanna

Barsoum

Arman

et al. 2019

Kidney International

View full text Add to dashboard Cite

“…E. Morale и соавт. наблюдали ухудшение почечной функции у пациента с морфологически подтвержденной диабетической нефропатией после интравитреального введения ранибизумаба [36].…”

Section: íàðóøåíèå ôóíêöèè ïî÷åêunclassified

Nephrotoxicity of anti-angiogenesis drugs

Grechukhina

Chebotareva

Krasnova

2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Neoangiogenesis is a basic factor for most physiological as well as pathological processes i.e. tumor metastases. The most important is vascular endothelium growth factor (VEGF) and its receptors (VEGFR1/2) in angiogenesis processes. Nowadays antiangiogenic agents (which inhibit VEGF like bevacizumab neither VEGFR2 like ramucirumab) are widely used in very different chemotherapeutic regimens in clinical oncology. The signalling pathway VEGF-VEGFR plays a crucial role in supporting of adequate kidney function. Appearance of antiangiogenic drugs led to adverse nephrotoxic effects: arterial hypertension, proteinuria, rarely nephrotic syndrome, and kidney dysfunction. Various hystological variants of nephropathy are described, however, in most cases, signs of thrombotic microangiopathy of the renal vessels are noted. This literature review discusses mechanisms, clinical and morphological aspects of nephropathy associated with antiangiogenic drugs.

show abstract

“…In contrast, intravitreal anti-VEGF therapy has traditionally not been felt to be associated with significant systemic toxicity, particularly given the dose of intravitreal anti-VEGF therapy is up to 400 times lower than that used systemically. 5 However, intravitreal anti-VEGF is cleared via the systemic circulation, and elevated serum levels of the specific anti-VEGF agents and decreased levels of VEGF itself can be observed following intravitreal injection. 6…”

Section: Introductionmentioning

confidence: 99%

Worsening Proteinuria Following Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema

Kenworthy

Davis

Chandra

et al. 2018

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

Intravitreal antivascular endothelial growth factor (anti-VEGF) therapy is a standard of care for a variety of ophthalmological conditions. While the systemic use of these agents in oncology is well known to induce a number of renal-related adverse effects such as worsening hypertension and proteinuria, the ability of local intravitreal injections to cause similar side effects has traditionally been thought to be unlikely given the lower doses used. In this case report, we describe an 88-year-old woman who developed a sudden worsening of her previously stable proteinuria with the use of bilateral intravitreal bevacizumab injections for diabetic macular edema, with improvement in her proteinuria upon reduction to unilateral therapy. This case report adds to the growing body of literature that suggests that local anti-VEGF therapy may have the potential to induce adverse systemic effects, and clinicians who care for these patients should remain vigilant to the development of potential renal-related toxicity.

show abstract

Renal damage associated to intravitreal administration of ranibizumab

Cited by 12 publications

References 9 publications

Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence

Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence

Nephrotoxicity of anti-angiogenesis drugs

Worsening Proteinuria Following Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema

Contact Info

Product

Resources

About